Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR Trial
Hidden mutations detectable in blood predict treatment failure in colorectal cancer patients, suggesting which patients need different drug combinations from the start.
In RAS wild-type mCRC patients, pre-treatment ctDNA reveals emergent RAS mutations in 44% of cases, which confer dramatically worse OS on FOLFIRI+ramucirumab and correlate with elevated IL-8 suggesting an inflammatory-resistance axis. These findings have direct implications for patient selection and combination therapy strategies in second-line mCRC.
What the study was
- Study design
- Translational biomarker substudy embedded in a clinical trial (JACCRO CC-16)
- Population
- RAS wild-type metastatic colorectal cancer patients receiving FOLFIRI+ramucirumab after prior anti-EGFR therapy (n=41 evaluable)
- Sample size
- 41
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Targeted Oncology
Why it surfaced
Important biomarker finding in mCRC second-line therapy; RAS clonal evolution detected by ctDNA in 44% despite wild-type tissue; n=41 limits confidence; multi-center Japanese trial adds real-world validity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.